The public-private partnership which is supported by 22 companies, NAIST, RIKEN and many universities will organize a collaborative screening consortium (drug-discovery innovation and screening consortium, DISC) based on 200,000 compounds from these companies. One aspect will also be to develop drugs for rare diseases.

AMED news release, December 24, 2015